Wendy Jo Levin
60 works · 19,995 citations · h-index 14
Top works
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group.
- Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study
- Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
- Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology
- Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial
- A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
- Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies
- Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
- The murine eosinophil peroxidase gene (Epx) maps to chromosome 11
- First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors
- Phase 1, open‐label, dose escalation, safety, and pharmacokinetics study of ME‐344 as a single agent in patients with refractory solid tumors
- Bispecific humanized anti-IL-2 receptor alpha beta antibodies inhibitory for both IL-2- and IL-15-mediated proliferation
- Phase I study of PF-03446962, a fully human mab against ALK 1, a TGFβ receptor involved in tumor angiogenesis.
- Tumor Suppressor and Immediate Early Transcription Factor Genes in Non-small Cell Lung Cancer
- Human Blast Crisis Leukemia Stem Cell Inhibition with a Novel Smoothened Antagonist.
- First-in-human, phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.
- Cycling Toward Leukemia Stem Cell Elimination Wtih a Selective Sonic Hedgehog Antagonist,